Everolimus (Afinitor®)
Oncology
ANDA ApprovedLaunched Q1 2025
Key Facts
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, founded in 2002 and publicly traded (NYSE: AMRX), has evolved from a generic drug company into a diversified biopharmaceutical enterprise with a mission to make medicine accessible for all. Its strategy is built on a three-pillar portfolio of complex generics, biosimilars, and specialty injectables, supported by significant U.S. manufacturing reinvestment. Recent high-profile launches like Brekiya for migraine and CREXONT for Parkinson's disease demonstrate its capability to develop and commercialize advanced, difficult-to-formulate products that address unmet patient needs and generate sustainable growth.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |
| Personalized Medicine Assays (Patient-Derived Explants) | Aurita Bioscience | Research-Use Only |
| CDK2-CyclinE1 & CDK2-CyclinA2 Assay | Aurora Biolabs | Commercial |
| POLQ & eIF4E Assay | Aurora Biolabs | Commercial |
| PKMYT1 & WEE1 Assay | Aurora Biolabs | Commercial |
| NTP42 | ATXA Therapeutics | Preclinical |
| Athebody® DARPins for pHLA-binding T-Cell Engagers | Athebio | Pre-clinical |
| Dual-Targeting CAR-T Programs | Factor Bioscience | Pre-clinical |